nodes	percent_of_prediction	percent_of_DWPC	metapath
Thiabendazole—Lansoprazole—CYP3A4—bone cancer	0.0762	1	CrCbGaD
Thiabendazole—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.0706	0.139	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0363	0.0715	CbGpPWpGaD
Thiabendazole—CYP1A1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.0332	0.0653	CbGpPWpGaD
Thiabendazole—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.0259	0.0509	CbGpPWpGaD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0232	0.0456	CbGpPWpGaD
Thiabendazole—CYP1A1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.021	0.0412	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen metabolism—CYP3A4—bone cancer	0.0191	0.0375	CbGpPWpGaD
Thiabendazole—CYP1A1—Xenobiotics—CYP3A4—bone cancer	0.0175	0.0345	CbGpPWpGaD
Thiabendazole—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.0169	0.0332	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.0156	0.0308	CbGpPWpGaD
Thiabendazole—Liver injury—Cisplatin—bone cancer	0.0154	0.037	CcSEcCtD
Thiabendazole—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.0134	0.0263	CbGpPWpGaD
Thiabendazole—Hepatocellular injury—Cisplatin—bone cancer	0.0129	0.0311	CcSEcCtD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0125	0.0246	CbGpPWpGaD
Thiabendazole—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.0122	0.0239	CbGpPWpGaD
Thiabendazole—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.0117	0.0229	CbGpPWpGaD
Thiabendazole—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.0112	0.022	CbGpPWpGaD
Thiabendazole—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.0108	0.0211	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.00997	0.0196	CbGpPWpGaD
Thiabendazole—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.00989	0.0194	CbGpPWpGaD
Thiabendazole—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.00901	0.0177	CbGpPWpGaD
Thiabendazole—Liver injury—Epirubicin—bone cancer	0.00789	0.019	CcSEcCtD
Thiabendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00732	0.0144	CbGpPWpGaD
Thiabendazole—Liver injury—Doxorubicin—bone cancer	0.0073	0.0176	CcSEcCtD
Thiabendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00728	0.0143	CbGpPWpGaD
Thiabendazole—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00719	0.0141	CbGpPWpGaD
Thiabendazole—Coordination abnormal—Epirubicin—bone cancer	0.00676	0.0163	CcSEcCtD
Thiabendazole—Hepatocellular injury—Epirubicin—bone cancer	0.00664	0.016	CcSEcCtD
Thiabendazole—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00631	0.0124	CbGpPWpGaD
Thiabendazole—Visual impairment—Cisplatin—bone cancer	0.00626	0.0151	CcSEcCtD
Thiabendazole—Coordination abnormal—Doxorubicin—bone cancer	0.00626	0.0151	CcSEcCtD
Thiabendazole—Hepatocellular injury—Doxorubicin—bone cancer	0.00614	0.0148	CcSEcCtD
Thiabendazole—Tinnitus—Cisplatin—bone cancer	0.00605	0.0146	CcSEcCtD
Thiabendazole—Lymphadenopathy—Methotrexate—bone cancer	0.00604	0.0145	CcSEcCtD
Thiabendazole—Flushing—Cisplatin—bone cancer	0.00603	0.0145	CcSEcCtD
Thiabendazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.0059	0.0116	CbGpPWpGaD
Thiabendazole—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.00574	0.0113	CbGpPWpGaD
Thiabendazole—Hepatic failure—Methotrexate—bone cancer	0.00573	0.0138	CcSEcCtD
Thiabendazole—Lymphadenopathy—Epirubicin—bone cancer	0.00565	0.0136	CcSEcCtD
Thiabendazole—Hepatic failure—Epirubicin—bone cancer	0.00536	0.0129	CcSEcCtD
Thiabendazole—Vision blurred—Cisplatin—bone cancer	0.00533	0.0128	CcSEcCtD
Thiabendazole—Lymphadenopathy—Doxorubicin—bone cancer	0.00523	0.0126	CcSEcCtD
Thiabendazole—Leukopenia—Cisplatin—bone cancer	0.00506	0.0122	CcSEcCtD
Thiabendazole—Hepatic failure—Doxorubicin—bone cancer	0.00496	0.012	CcSEcCtD
Thiabendazole—Convulsion—Cisplatin—bone cancer	0.0049	0.0118	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00486	0.00955	CbGpPWpGaD
Thiabendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00464	0.00913	CbGpPWpGaD
Thiabendazole—Anaphylactic shock—Cisplatin—bone cancer	0.00461	0.0111	CcSEcCtD
Thiabendazole—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00458	0.00901	CbGpPWpGaD
Thiabendazole—Anorexia—Cisplatin—bone cancer	0.0044	0.0106	CcSEcCtD
Thiabendazole—Hypotension—Cisplatin—bone cancer	0.00431	0.0104	CcSEcCtD
Thiabendazole—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.00414	0.00814	CbGpPWpGaD
Thiabendazole—Decreased appetite—Cisplatin—bone cancer	0.00401	0.00966	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00399	0.00785	CbGpPWpGaD
Thiabendazole—Drowsiness—Methotrexate—bone cancer	0.00397	0.00956	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00393	0.00948	CcSEcCtD
Thiabendazole—Feeling abnormal—Cisplatin—bone cancer	0.0038	0.00916	CcSEcCtD
Thiabendazole—Haematuria—Methotrexate—bone cancer	0.00378	0.00912	CcSEcCtD
Thiabendazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00376	0.0074	CbGpPWpGaD
Thiabendazole—Hyperglycaemia—Epirubicin—bone cancer	0.00376	0.00905	CcSEcCtD
Thiabendazole—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	0.00373	0.00734	CbGpPWpGaD
Thiabendazole—Drowsiness—Epirubicin—bone cancer	0.00371	0.00895	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00368	0.00887	CcSEcCtD
Thiabendazole—Jaundice—Epirubicin—bone cancer	0.00362	0.00872	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.0036	0.00708	CbGpPWpGaD
Thiabendazole—Haematuria—Epirubicin—bone cancer	0.00354	0.00853	CcSEcCtD
Thiabendazole—Hyperglycaemia—Doxorubicin—bone cancer	0.00348	0.00838	CcSEcCtD
Thiabendazole—Drowsiness—Doxorubicin—bone cancer	0.00344	0.00828	CcSEcCtD
Thiabendazole—Visual impairment—Methotrexate—bone cancer	0.00343	0.00827	CcSEcCtD
Thiabendazole—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00341	0.00821	CcSEcCtD
Thiabendazole—Hypersensitivity—Cisplatin—bone cancer	0.0034	0.00819	CcSEcCtD
Thiabendazole—Erythema multiforme—Methotrexate—bone cancer	0.00337	0.00812	CcSEcCtD
Thiabendazole—Jaundice—Doxorubicin—bone cancer	0.00335	0.00807	CcSEcCtD
Thiabendazole—Tinnitus—Methotrexate—bone cancer	0.00332	0.008	CcSEcCtD
Thiabendazole—Hypoaesthesia—Epirubicin—bone cancer	0.00332	0.00799	CcSEcCtD
Thiabendazole—Asthenia—Cisplatin—bone cancer	0.00331	0.00797	CcSEcCtD
Thiabendazole—Haematuria—Doxorubicin—bone cancer	0.00328	0.00789	CcSEcCtD
Thiabendazole—Visual impairment—Epirubicin—bone cancer	0.00321	0.00774	CcSEcCtD
Thiabendazole—Chills—Methotrexate—bone cancer	0.0032	0.0077	CcSEcCtD
Thiabendazole—Diarrhoea—Cisplatin—bone cancer	0.00316	0.0076	CcSEcCtD
Thiabendazole—Erythema multiforme—Epirubicin—bone cancer	0.00315	0.00759	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—CYP3A4—bone cancer	0.00314	0.00617	CbGpPWpGaD
Thiabendazole—Tinnitus—Epirubicin—bone cancer	0.00311	0.00749	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.0031	0.00609	CbGpPWpGaD
Thiabendazole—Flushing—Epirubicin—bone cancer	0.00309	0.00745	CcSEcCtD
Thiabendazole—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.00309	0.00608	CbGpPWpGaD
Thiabendazole—Hypoaesthesia—Doxorubicin—bone cancer	0.00307	0.00739	CcSEcCtD
Thiabendazole—Chills—Epirubicin—bone cancer	0.00299	0.00721	CcSEcCtD
Thiabendazole—Visual impairment—Doxorubicin—bone cancer	0.00297	0.00716	CcSEcCtD
Thiabendazole—Vomiting—Cisplatin—bone cancer	0.00293	0.00707	CcSEcCtD
Thiabendazole—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.00292	0.00575	CbGpPWpGaD
Thiabendazole—Vision blurred—Methotrexate—bone cancer	0.00292	0.00704	CcSEcCtD
Thiabendazole—Erythema multiforme—Doxorubicin—bone cancer	0.00292	0.00703	CcSEcCtD
Thiabendazole—Rash—Cisplatin—bone cancer	0.00291	0.00701	CcSEcCtD
Thiabendazole—Dermatitis—Cisplatin—bone cancer	0.00291	0.007	CcSEcCtD
Thiabendazole—Tinnitus—Doxorubicin—bone cancer	0.00288	0.00693	CcSEcCtD
Thiabendazole—Flushing—Doxorubicin—bone cancer	0.00286	0.0069	CcSEcCtD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00283	0.00556	CbGpPWpGaD
Thiabendazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.00283	0.00556	CbGpPWpGaD
Thiabendazole—Leukopenia—Methotrexate—bone cancer	0.00278	0.00669	CcSEcCtD
Thiabendazole—Chills—Doxorubicin—bone cancer	0.00277	0.00667	CcSEcCtD
Thiabendazole—Nausea—Cisplatin—bone cancer	0.00274	0.0066	CcSEcCtD
Thiabendazole—Vision blurred—Epirubicin—bone cancer	0.00274	0.00659	CcSEcCtD
Thiabendazole—Convulsion—Methotrexate—bone cancer	0.00269	0.00647	CcSEcCtD
Thiabendazole—CYP1A1—Biological oxidations—GSTP1—bone cancer	0.00268	0.00527	CbGpPWpGaD
Thiabendazole—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	0.00265	0.0052	CbGpPWpGaD
Thiabendazole—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.00264	0.00519	CbGpPWpGaD
Thiabendazole—Leukopenia—Epirubicin—bone cancer	0.0026	0.00626	CcSEcCtD
Thiabendazole—Confusional state—Methotrexate—bone cancer	0.00255	0.00615	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00255	0.005	CbGpPWpGaD
Thiabendazole—Anaphylactic shock—Methotrexate—bone cancer	0.00253	0.0061	CcSEcCtD
Thiabendazole—Vision blurred—Doxorubicin—bone cancer	0.00253	0.0061	CcSEcCtD
Thiabendazole—Convulsion—Epirubicin—bone cancer	0.00251	0.00606	CcSEcCtD
Thiabendazole—Anorexia—Methotrexate—bone cancer	0.00241	0.00581	CcSEcCtD
Thiabendazole—Leukopenia—Doxorubicin—bone cancer	0.0024	0.00579	CcSEcCtD
Thiabendazole—Confusional state—Epirubicin—bone cancer	0.00239	0.00575	CcSEcCtD
Thiabendazole—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.00238	0.00468	CbGpPWpGaD
Thiabendazole—Anaphylactic shock—Epirubicin—bone cancer	0.00237	0.00571	CcSEcCtD
Thiabendazole—Hypotension—Methotrexate—bone cancer	0.00237	0.0057	CcSEcCtD
Thiabendazole—Convulsion—Doxorubicin—bone cancer	0.00233	0.00561	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.00229	0.00451	CbGpPWpGaD
Thiabendazole—Anorexia—Epirubicin—bone cancer	0.00226	0.00544	CcSEcCtD
Thiabendazole—Somnolence—Methotrexate—bone cancer	0.00225	0.00542	CcSEcCtD
Thiabendazole—Dyspepsia—Methotrexate—bone cancer	0.00223	0.00537	CcSEcCtD
Thiabendazole—Hypotension—Epirubicin—bone cancer	0.00221	0.00533	CcSEcCtD
Thiabendazole—Confusional state—Doxorubicin—bone cancer	0.00221	0.00532	CcSEcCtD
Thiabendazole—Decreased appetite—Methotrexate—bone cancer	0.0022	0.0053	CcSEcCtD
Thiabendazole—Anaphylactic shock—Doxorubicin—bone cancer	0.00219	0.00528	CcSEcCtD
Thiabendazole—Fatigue—Methotrexate—bone cancer	0.00218	0.00526	CcSEcCtD
Thiabendazole—Somnolence—Epirubicin—bone cancer	0.00211	0.00507	CcSEcCtD
Thiabendazole—Anorexia—Doxorubicin—bone cancer	0.00209	0.00503	CcSEcCtD
Thiabendazole—Feeling abnormal—Methotrexate—bone cancer	0.00209	0.00502	CcSEcCtD
Thiabendazole—Dyspepsia—Epirubicin—bone cancer	0.00209	0.00502	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Methotrexate—bone cancer	0.00207	0.00499	CcSEcCtD
Thiabendazole—Decreased appetite—Epirubicin—bone cancer	0.00206	0.00496	CcSEcCtD
Thiabendazole—Hypotension—Doxorubicin—bone cancer	0.00205	0.00493	CcSEcCtD
Thiabendazole—Fatigue—Epirubicin—bone cancer	0.00204	0.00492	CcSEcCtD
Thiabendazole—Abdominal pain—Methotrexate—bone cancer	0.002	0.00482	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.002	0.00393	CbGpPWpGaD
Thiabendazole—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.00197	0.00388	CbGpPWpGaD
Thiabendazole—Feeling abnormal—Epirubicin—bone cancer	0.00195	0.0047	CcSEcCtD
Thiabendazole—Somnolence—Doxorubicin—bone cancer	0.00195	0.00469	CcSEcCtD
Thiabendazole—Gastrointestinal pain—Epirubicin—bone cancer	0.00194	0.00467	CcSEcCtD
Thiabendazole—Dyspepsia—Doxorubicin—bone cancer	0.00193	0.00465	CcSEcCtD
Thiabendazole—Decreased appetite—Doxorubicin—bone cancer	0.00191	0.00459	CcSEcCtD
Thiabendazole—Fatigue—Doxorubicin—bone cancer	0.00189	0.00455	CcSEcCtD
Thiabendazole—CYP1A1—Metabolism—NDUFA12—bone cancer	0.00188	0.0037	CbGpPWpGaD
Thiabendazole—Abdominal pain—Epirubicin—bone cancer	0.00187	0.00451	CcSEcCtD
Thiabendazole—Hypersensitivity—Methotrexate—bone cancer	0.00187	0.00449	CcSEcCtD
Thiabendazole—Asthenia—Methotrexate—bone cancer	0.00182	0.00438	CcSEcCtD
Thiabendazole—Feeling abnormal—Doxorubicin—bone cancer	0.00181	0.00435	CcSEcCtD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.0018	0.00355	CbGpPWpGaD
Thiabendazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.0018	0.00355	CbGpPWpGaD
Thiabendazole—Gastrointestinal pain—Doxorubicin—bone cancer	0.00179	0.00432	CcSEcCtD
Thiabendazole—Pruritus—Methotrexate—bone cancer	0.00179	0.00431	CcSEcCtD
Thiabendazole—Hypersensitivity—Epirubicin—bone cancer	0.00175	0.0042	CcSEcCtD
Thiabendazole—Abdominal pain—Doxorubicin—bone cancer	0.00173	0.00417	CcSEcCtD
Thiabendazole—Diarrhoea—Methotrexate—bone cancer	0.00173	0.00417	CcSEcCtD
Thiabendazole—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.00171	0.00336	CbGpPWpGaD
Thiabendazole—Asthenia—Epirubicin—bone cancer	0.0017	0.00409	CcSEcCtD
Thiabendazole—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.00169	0.00332	CbGpPWpGaD
Thiabendazole—Pruritus—Epirubicin—bone cancer	0.00168	0.00404	CcSEcCtD
Thiabendazole—Dizziness—Methotrexate—bone cancer	0.00167	0.00403	CcSEcCtD
Thiabendazole—Diarrhoea—Epirubicin—bone cancer	0.00162	0.0039	CcSEcCtD
Thiabendazole—Hypersensitivity—Doxorubicin—bone cancer	0.00161	0.00389	CcSEcCtD
Thiabendazole—Vomiting—Methotrexate—bone cancer	0.00161	0.00388	CcSEcCtD
Thiabendazole—Rash—Methotrexate—bone cancer	0.0016	0.00384	CcSEcCtD
Thiabendazole—Dermatitis—Methotrexate—bone cancer	0.00159	0.00384	CcSEcCtD
Thiabendazole—Headache—Methotrexate—bone cancer	0.00159	0.00382	CcSEcCtD
Thiabendazole—Asthenia—Doxorubicin—bone cancer	0.00157	0.00379	CcSEcCtD
Thiabendazole—Dizziness—Epirubicin—bone cancer	0.00157	0.00377	CcSEcCtD
Thiabendazole—CYP1A1—Metabolism—NT5C3A—bone cancer	0.00156	0.00306	CbGpPWpGaD
Thiabendazole—Pruritus—Doxorubicin—bone cancer	0.00155	0.00374	CcSEcCtD
Thiabendazole—Vomiting—Epirubicin—bone cancer	0.00151	0.00363	CcSEcCtD
Thiabendazole—Nausea—Methotrexate—bone cancer	0.0015	0.00362	CcSEcCtD
Thiabendazole—Diarrhoea—Doxorubicin—bone cancer	0.0015	0.00361	CcSEcCtD
Thiabendazole—Rash—Epirubicin—bone cancer	0.00149	0.0036	CcSEcCtD
Thiabendazole—Dermatitis—Epirubicin—bone cancer	0.00149	0.00359	CcSEcCtD
Thiabendazole—Headache—Epirubicin—bone cancer	0.00148	0.00357	CcSEcCtD
Thiabendazole—Dizziness—Doxorubicin—bone cancer	0.00145	0.00349	CcSEcCtD
Thiabendazole—Nausea—Epirubicin—bone cancer	0.00141	0.00339	CcSEcCtD
Thiabendazole—Vomiting—Doxorubicin—bone cancer	0.00139	0.00336	CcSEcCtD
Thiabendazole—Rash—Doxorubicin—bone cancer	0.00138	0.00333	CcSEcCtD
Thiabendazole—Dermatitis—Doxorubicin—bone cancer	0.00138	0.00333	CcSEcCtD
Thiabendazole—Headache—Doxorubicin—bone cancer	0.00137	0.00331	CcSEcCtD
Thiabendazole—Nausea—Doxorubicin—bone cancer	0.0013	0.00314	CcSEcCtD
Thiabendazole—CYP1A2—Metabolism—NDUFA12—bone cancer	0.0012	0.00236	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—NT5C3A—bone cancer	0.000993	0.00195	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—ENO2—bone cancer	0.000682	0.00134	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—DHFR—bone cancer	0.000633	0.00124	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GNA11—bone cancer	0.000592	0.00116	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—CYP3A4—bone cancer	0.000536	0.00105	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000534	0.00105	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—GSTP1—bone cancer	0.000459	0.000902	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—ENO2—bone cancer	0.000435	0.000855	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—DHFR—bone cancer	0.000404	0.000794	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GNA11—bone cancer	0.000377	0.000742	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—CYP3A4—bone cancer	0.000342	0.000672	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.00034	0.000669	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—GSTP1—bone cancer	0.000293	0.000575	CbGpPWpGaD
Thiabendazole—CYP1A1—Metabolism—PTGS2—bone cancer	0.000238	0.000467	CbGpPWpGaD
Thiabendazole—CYP1A2—Metabolism—PTGS2—bone cancer	0.000152	0.000298	CbGpPWpGaD
